Stuart Poulton - 15 Feb 2023 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Development Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Stuart Poulton
Issuer symbol
KPTI
Transactions as of
15 Feb 2023
Net transactions value
-$18,717
Form type
4
Filing time
17 Feb 2023, 15:07:57 UTC
Previous filing
19 Aug 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale $18,071 -5,665 -8.1% $3.19 64,335 15 Feb 2023 Direct F1
transaction KPTI Common Stock Sale $25.84 -8 -0.01% $3.23 64,327 15 Feb 2023 Direct F1
transaction KPTI Common Stock Sale $619 -196 -0.3% $3.16 64,131 15 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.